| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: VLRX |
| Security Type |
Common Stock |
| Lead Underwriter |
UBS Investment Bank Banc of America Securities LLC |
| Days In Registration |
324 |
| Date Filed |
14-Mar-2005 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Manufacturing |
| Business Description |
Manufacture specialty pharmaceuticals focused on the development and commercialization of urology and endocrinology products |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
14.7M |
| Contact |
- |
| Number of Employees |
- |
|
| Original Filing Information |
| US |
| Shares Filed |
3.75M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
3.75M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
562.5K |
| File Amount |
$41.25M |
| File Price Range |
$12.00 - $10.00 |
| File Mid Price |
$11.00 |
Current Filing Information
(Amended 30-Jan-2006) |
|
US |
|
Shares Filed |
3.75M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
3.75M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$41.25M |
| · % Change from Original |
0.0 |
| File Price Range |
$12.00 - $10.00 |
| File Mid Price |
$11.00 |
|
